Kavash Robert W
Janssen Pharmaceutica
22 Papers
162 Citations
Kavash Robert W is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Opioid receptor & Opioid. The author has an hindex of 7, co-authored 22 publications. Previous affiliations of Kavash Robert W include Johnson & Johnson & Johnson & Johnson Pharmaceutical Research and Development.
Chat about Author
Papers
Patent
Novel compounds as opioid receptor modulators
Henry J. Breslin,Chaozhong Cai,Wei He,Kavash Robert W +3 more
- 14 Mar 2005
TL;DR: In this article, the authors present methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
52
Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
Henry J. Breslin,Craig J. Diamond,Kavash Robert W,Chaozhong Cai,Alexey B. Dyatkin,Tamara A. Miskowski,Sui-Po Zhang,Paul R. Wade,Pamela J. Hornby,Wei He +9 more
TL;DR: Compound 5l has progressed through a clinical Phase II Proof of Concept study on 800 patients suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-d), with 5l demonstrating statistically significant efficacy over placebo.
51
Patent
Prodrugs of HIV replication inhibiting pyrimidines
Kukla Michael Joseph,Donald William Ludovici,Kavash Robert W,Bart De Corte,Jan Heeres,Paul Adriaan Jan Janssen,Lucien Maria Henricus Koymans,Jonge Marc Rene De,Aken Koen Jeanne Alfons Van,Alain Krief +9 more
- 03 May 2001
TL;DR: In this article, the authors present compounds of the formula (I): (A1)(A2)N-R1, the Noxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof.
48
Patent
Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections
Daeyaert Frederik Frans Desire,Bart De Corte,Jonge Marc Rene De,Jan Heeres,Chih Yung Ho,Janssen Paul Adriaan Jan,Kavash Robert W,Lucien Maria Henricus Koymans,Kukla Michael Joseph,Donald William Ludovici +9 more
- 24 Mar 1999
TL;DR: In this paper, the use of the compounds of formula (I) the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, where A is CH, CR4 or N; n is 0, 1, 2, 3 or 4; R?1 and R2? are each independently selected from hydrogen, hydroxy, C?1-12?alkyl, C 1-12-oxy, C1- 12-12alkyl-group, aryl, amino, amino amino, mono-
26
Tripeptidyl-peptidase II (TPP II) inhibitory activity of (S)-2,3-dihydro-2-(1H-imidazol-2-yl)-1H-indoles, a systematic SAR evaluation. Part 2.
Henry J. Breslin,Tamara A. Miskowski,Michael Joseph Kukla,Hans De Winter,Maria V. F. Somers,Peter Walter Maria Roevens,Kavash Robert W +6 more
TL;DR: This SAR evaluation of the core structure of TPP II suggest a fairly restrictive pharmacophore for such related structures, but has yielded a limited set of compounds with potent TPP II inhibitory activity.
18